Alnylam (ALNY) Stock
Fundamentals
Source: third-party data provider, as of October 14, 2026
Compare with ALNY
Recent news

Alnylam vs. Ionis: Here's the Better Bad-News Buy
Alnylam vs. Ionis: Here's the Better Bad-News Buy
ALNY

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
ALNY

AMVUTTRA® (vutrisiran) ‘Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
AMVUTTRA® (vutrisiran) ‘Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
ALNY

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
ALNY
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 39.86
- MACD 12/26/9
- -5.93
- EMA 9 of MACD
- -4.41
- MACD histogram
- -1.52
- SMA 50
- $237.88
- Price below SMA 50
- EMA 50
- $244.09
- Price below EMA 50
- SMA 200
- $296.83
- Price below SMA 200
- EMA 200
- $304.81
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 15 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.56 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Alnylam vs. Ionis: Here's the Better Bad-News Buy
Alnylam vs. Ionis: Here's the Better Bad-News Buy
ALNY

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
ALNY

AMVUTTRA® (vutrisiran) ‘Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
AMVUTTRA® (vutrisiran) ‘Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
ALNY

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
ALNY

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
ALNY

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
ALNY

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
ALNY

Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
ALNY

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
ALNY

Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
ALNY
News tone: automated (AI) classification of the article's content, not a price prediction.
About Alnylam
Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Yvonne L. Greenstreet M.B.A., M.D. | CEO & Director | 1963 |
| Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP | 1968 |
| Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board | 1945 |
| Mr. Bryan Andrew Supran J.D. | Chief Legal Officer | 1970 |
| Dr. Pushkal P. Garg M.D. | Executive VP & Chief Research & Development Officer | 1968 |
| Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercialization Officer | 1973 |
| Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer | — |
| Dr. Kevin Joseph Fitzgerald Ph.D. | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development | 1968 |
| Mr. Joshua Brodsky | Vice President of Investor Relations | — |
| Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 14, 2026
Technical indicators
- RSI 14
- 39.86
- MACD 12/26/9
- -5.93
- EMA 9 of MACD
- -4.41
- MACD histogram
- -1.52
- SMA 50
- $237.88
- Price below SMA 50
- EMA 50
- $244.09
- Price below EMA 50
- SMA 200
- $296.83
- Price below SMA 200
- EMA 200
- $304.81
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst views
15 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $256.00
- Average
- $351.87
- High
- $455.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -23.5 | +10.5 | -5.8 | |||||||||
| 2022 | -20.9 | +8.9 | +0.5 | -21.2 | -9.5 | +18.5 | -4.2 | +47.7 | -5.2 | +5.3 | +3.5 | +7.9 |
| 2023 | -3.1 | -14.9 | +2.5 | -0.7 | -8.4 | +0.7 | +3.0 | +4.6 | -12.0 | -15.2 | +7.2 | +11.7 |
| 2024 | -11.3 | -13.6 | -2.1 | -6.1 | -1.0 | +61.5 | -2.4 | -2.2 | +8.4 | -3.4 | -7.6 | -7.0 |
| 2025 | +16.1 | -10.1 | +10.9 | +2.9 | +19.4 | +6.5 | +21.8 | +11.1 | +2.0 | -1.0 | +4.0 | -12.5 |
| 2026 | -15.5 | -1.8 | +1.8 | -5.9 | +2.0 | +1.8 | -31.9 | +9.2 | +0.3 | -3.2 |




